|
|||||
|
|
||||||
Originally published as JCO Early Release 10.1200/JCO.2007.15.4864 on December 29 2008 © 2009 American Society of Clinical Oncology.
Predictors of Referral for Specialized Psychosocial Oncology Care in Patients With Metastatic Cancer: The Contributions of Age, Distress, and Marital StatusFrom the Departments of Psychosocial Oncology and Palliative Care, and Medical Oncology, Princess Margaret Hospital; Psychosocial Oncology and Palliative Care Research Division, Ontario Cancer Institute, University Health Network; Behavioural Sciences and Health Research Division, Toronto General Research Institute, University Health Network; University of Toronto; and the Department of Kinesiology and Health Science, York University, Toronto, Ontario, Canada. Corresponding author: Gary Rodin, MD, Department of Psychosocial Oncology and Palliative Care, Princess Margaret Hospital, University Health Network, 16th Floor, Room 724, 610 University Avenue, Toronto, Ontario M5G 2M9 Canada; e-mail: gary.rodin{at}uhn.on.ca. Purpose This study examines the rate and prediction of referral for specialized psychosocial oncology care in 326 patients with metastatic GI or lung cancer. Patients and Methods Referral information was abstracted from medical records and hospital databases. Patients completed measures of psychosocial and physical distress and functioning.
Results Routine referral occurred in 33% of patients, and in 42% and 44%, respectively, of those scoring high on measures of depression (Beck Depression Inventory [BDI]-II Conclusion Routine referral of patients with metastatic cancer for psychosocial oncology care was predicted by presence of more severe depressive symptoms, younger age, and unmarried status. The rate of referral progressively declined with each decade of age, even among those with significant distress. These findings are consistent with some aspects of Andersen's model of health care utilization. The extent to which referred patients represent those who are most likely to benefit deserves further investigation. Supported by grants from the Canadian Institutes of Health Research (CIHR Grant No. MOP-62861; G.R.) and York University (L.G.), and by the Edith Kirchmann Fellowship from Princess Margaret Hospital (C.L.). Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Related Article
Related Editorials
This article has been cited by other articles:
|
|||||||||||||
|
|||||||||||
|
Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|